377 related articles for article (PubMed ID: 25432358)
1. Current and future treatments of osteoporosis in men.
Kaufman JM; Lapauw B; Goemaere S
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):871-84. PubMed ID: 25432358
[TBL] [Abstract][Full Text] [Related]
2. Treatment of primary osteoporosis in men.
Giusti A; Bianchi G
Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
[TBL] [Abstract][Full Text] [Related]
3. [Osteoporosis].
Uebelhart B; Rizzoli R
Rev Med Suisse; 2015 Jan; 11(456-457):108-13. PubMed ID: 25799662
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
5. Future directions for new medical entities in osteoporosis.
Ferrari S
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
7. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
Langdahl B
Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
[TBL] [Abstract][Full Text] [Related]
8. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
9. Established and forthcoming drugs for the treatment of osteoporosis.
Lems WF; Geusens P
Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
[TBL] [Abstract][Full Text] [Related]
10. Romosozumab: A Review in Postmenopausal Osteoporosis.
Paik J; Scott LJ
Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
[TBL] [Abstract][Full Text] [Related]
11. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
13. Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.
Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kodama Y; Kato Y
Osteoporos Int; 2022 Jun; 33(6):1265-1273. PubMed ID: 35059774
[TBL] [Abstract][Full Text] [Related]
14. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
Gasser JA
Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
[TBL] [Abstract][Full Text] [Related]
15. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
17. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
18. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
19. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
20. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
